Stockscreener 앱 받기
10.74
9.36%
-1.12
전일 마감가:
$11.86
열려 있는:
$11.22
하루 거래량:
1.59M
Relative Volume:
1.22
시가총액:
$586.03M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-12.94
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-16.21%
1개월 성능:
+18.65%
6개월 성능:
-41.73%
1년 성능:
+96.53%
1일 변동 폭
$9.99
$11.32
1주일 범위
$9.99
$13.22
52주 변동 폭
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
10.73 | 586.03M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.57 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.35 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.76 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.45 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - Seeking Alpha
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan
Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World
Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel
Capricor Therapeutics Inc (CAPR) shows promising results - uspostnews.com
Capricor Therapeutics Inc (CAPR) receives an Overweight rating from Piper Sandler - knoxdaily.com
Legal & General Group Plc Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Capricor Therapeutics Inc’s Market Journey: Closing Weak at 12.83, Down -1.53 - DWinneX
Russell Investments Group Ltd. Grows Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc [NASDAQ: CAPR] Sees Increase in Stock Value - knoxdaily.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLC - Defense World
13,280 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Alliancebernstein L.P. - Defense World
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges and Strategic Advancements - GuruFocus
Former Novartis Deal Chief Who Led 50+ Strategic Transactions Joins OmniAb Board - Stock Titan
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - simplywall.st
Stock Traders Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR) - Defense World
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? - Yahoo
Wellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Corebridge Financial Inc. Has $251,000 Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
KLP Kapitalforvaltning AS Invests $91,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
(CAPR) Trading Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Buys Shares of 10,243 Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day - The Manila Times
Promising DMD Treatment Update: Capricor CEO Reveals Latest Development Progress - Stock Titan
Capricor Therapeutics Plunges 19.91% Amid Clinical Trials Focus - AInvest
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - simplywall.st
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
(CAPR) Trading Signals - Stock Traders Daily
Bank of New York Mellon Corp Purchases 20,638 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Capricor Therapeutics Inc 주식 (CAPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
0.28%
0.47%
자본화:
|
볼륨(24시간):